The Predictive Role of Intra-Tumoral CD8+T Cells with Stem Cell-Like Properties in Response to and Efficacy of Anti-PD-1/L1 Treatment
Received Date: Jan 19, 2022 / Published Date: Feb 15, 2022
Abstract
A Checkpoint Inhibitor-Based Immunotherapy (ICIs) has demonstrated outstanding efficacy in many solid tumors. However, some treated patients with positive expression of PD-L1 do not respond, and even develop hyper progression, and some patients with negative expression of PD-L1 can also benefit from immunotherapy combined with chemotherapy. There is growing need to identify biomarkers that will improve the selection of patients who will best respond to therapy. Intra-tumoral effective T cells are critical for anti-tumor effect, and some subpopulation of it have been verified as potential biomarkers for ICIs. In our previous study, a subset of intra-tumoral CD8+ T cells with stem-like properties has been identified as sensitive biomarker for predicting the response to and efficacy of PD-1/L1 blockade treatment with or without chemotherapy. In the current comment, the role and challenges of this cell subpopulation in anti-PD-1/L1 immunotherapy will be discussed.
Keywords: Non-small cell lung cancer; PD-1/L1 immunotherapy; CD8+ T cells; Biomarker
Citation: Fang X, Tang R, Chen R, Luo Z, Xu X, et al. (2022) The Predictive Role of Intra-Tumoral CD8+T Cells with Stem Cell-Like Properties in Response to and Efficacy of Anti-PD-1/L1 Treatment. J Oncol Res Treat S1: 002. Doi: 10.4172/aot.7.s1.1000002
Copyright: © 2022 Fang X, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Share This Article
Open Access Journals
Article Tools
Article Usage
- Total views: 1963
- [From(publication date): 0-2022 - Nov 18, 2024]
- Breakdown by view type
- HTML page views: 1623
- PDF downloads: 340
